Skip to main content

Table 5 Relationship between consumption of non-steroideal anti-inflammatory drugs and breast cancer, according to tumor characteristics

From: Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

Variable

Category

NSAID

Unexposed controls/cases (n)

Exposed controls/cases (n)

OR (95 % CI)

P

Clinical stage

1–2

NSAID (all)

1170/696

739/404

0.80 (0.66–0.97

0.02

Aspirin

1807/1047

102/52

0.93 (0.63–1.38)

0.72

Acetic acid derivatives

1753/1025

156/74

0.75 (0.54–1.06)

0.11

Propionic acid derivatives

1350/770

559/329

0.90 (0.74–1.11)

0.33

cox2 inhibitors

1891/1095

18/4

-

-

NSAID others

1861/1072

48/27

1.07 (0.61–1.90)

0.81

3–4

NSAID (all)

1170/136

739/68

0.74 (0.51–1.06)

0.10

Aspirin

1807/192

102/12

1.31 (0.66–2.59)

0.44

Acetic acid derivatives

1753/190

156/14

0.99 (0.53–1.83)

0.97

Propionic acid derivatives

1350/147

559/57

0.84 (0.57–1.24)

0.39

cox2 inhibitors

1891/204

18/0

-

-

NSAID others

1861/201

48/3

-

-

Pathology

Ductal cancer

NSAID (all)

1170/835

739/454

0.70 (0.58–0.84)

<0.001

Aspirin

1807/1225

102/64

0.97 (0.66–1.41)

0.86

Acetic acid derivatives

1753/1204

156/85

0.76 (0.55–1.06)

0.11

Propionic acid derivatives

1350/918

559/371

0.78 (0.64–0.95)

0.01

cox2 inhibitors

1891/1289

18/3

-

-

NSAID others

1861/1259

48/30

1.06 (0.60–1.87)

0.85

Non-ductal cancer

NSAID (all)

1170/151

739/83

0.82 (0.58–1.15)

0.25

Aspirin

1807/228

102/6

0.50 (0.21–1.19)

0.12

Acetic acid derivatives

1753/219

156/15

0.85 (0.46–1.58)

0.61

Propionic acid derivatives

1350/166

559/68

0.91 (0.63–1.31)

0.60

cox2 inhibitors

1891/234

18/0

-

-

NSAID others

1861/232

48/2

-

-

Inmunohistochemistry

Hormone +

NSAID (all)

1170/727

739/390

0.72 (0.60–0.88)

<0.001

Aspirin

1807/1069

102/48

0.82 (0.55–1.24)

0.35

Acetic acid derivatives

1753/1044

156/73

0.76 (0.54–1.08)

0.12

Propionic acid derivatives

1350/805

559/312

0.80 (0.65–0.98)

0.03

cox2 inhibitors

1891/1115

18/2

-

-

NSAID others

1861/1089

48/28

1.28 (0.73–2.25)

0.38

HER2+

NSAID (all)

1170/739

172/83

0.63 (0.45–0.88)

0.007

Aspirin

1807/102

244/11

0.79 (0.38–1.65)

0.53

Acetic acid derivatives

1753/238

156/17

0.67 (0.36–1.24)

0.20

Propionic acid derivatives

1350/188

559/67

0.66 (0.46–0.95)

0.03

cox2 inhibitors

1891/255

18/0

-

-

NSAID others

1861/251

48/4

-

-

Triple negative breast cancer

NSAID (all)

1170/94

739/63

0.87 (0.58–1.30)

0.49

Aspirin

1807/148

102/9

1.24 (0.57–2.71)

0.59

Acetic acid derivatives

1753/147

156/10

0.86 (0.41–1.79)

0.68

Propionic acid derivatives

1350/103

559/54

0.99 (0.64–1.52)

0.95

cox2 inhibitors

1891/156

18/1

-

-

NSAID others

1861/154

48/3

-

-

  1. OR Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first delivery, menarche age, and menopausal status. CI confidence interval